公开(公告)号：US20140315883A1

公开(公告)日：2014-10-23

申请号：US14256224

申请日：2014-04-18

Applicant: Eric Breinlinger ,  Heather Davis ,  Michael Hoemann ,  Bin Li ,  Biqin Li ,  Gagandeep Somal ,  Stacy Van Epps ,  Lu Wang ,  Lu Wang

Inventor： Eric Breinlinger ,  Heather Davis ,  Michael Hoemann ,  Bin Li ,  Biqin Li ,  Gagandeep Somal ,  Stacy Van Epps ,  Lu Wang ,  Lu Wang

IPC: C07D487/16

CPC classification number: C07D487/16 ,  C07D487/14

Abstract: The invention provides a compound of Formula (I as defined herein, pharmaceutically acceptable salts, pro-drugs, biologically active metabolites, stereoisomers and isomers thereof wherein the variables are defined herein. The compounds of the invention are useful for treating immunological and oncological conditions.

Abstract translation: 本发明提供了本文定义的式（I）化合物，其药学上可接受的盐，前药，生物活性代谢物，立体异构体和异构体，其中变量在本文中定义。本发明的化合物可用于治疗免疫学和肿瘤学病症。

公开(公告)号：US20100166819A1

公开(公告)日：2010-07-01

申请号：US12086954

申请日：2006-12-22

Applicant: Wen-Cherng Lee ,  Lihong Sun ,  Michael Hoemann ,  Deqiang Niu ,  Dingxue Yan ,  Claudio Chuaqui ,  Russell Petter ,  Helen (Xiaomei) Feng

Inventor： Wen-Cherng Lee ,  Lihong Sun ,  Michael Hoemann ,  Deqiang Niu ,  Dingxue Yan ,  Claudio Chuaqui ,  Russell Petter ,  Helen (Xiaomei) Feng

IPC: A61K31/55 ,  A61K9/00 ,  A61K31/502 ,  A61K31/517 ,  A61K31/438 ,  C07D487/10 ,  C07D401/14 ,  C07D403/14 ,  A61P35/00 ,  A61P9/12 ,  A61P9/10 ,  A61P27/02 ,  A61P1/16 ,  A61P13/12

CPC classification number: C07D487/10 ,  C07D471/10

Abstract: The invention is related to compounds of formula (I) that can be used as antagonists of the TGFβ family type I receptors, Alk5 and/or Alk4, compositions and methods of use. The compounds of formula (I) can be employed in the prevention and/or treatment of diseases such as fibrosis (e.g., renal fibrosis, pulmonary fibrosis, and hepatic fibrosis), progressive cancers, or other diseases for which reduction of TGFβ family signaling activity is desirable.

Abstract translation: 本发明涉及可用作TGFβb拮抗剂的式（I）化合物; 家族I型受体，Alk5和/或Alk4，组合物和使用方法。 式（I）化合物可用于预防和/或治疗诸如纤维化（例如肾纤维化，肺纤维化和肝纤维化），进行性癌症或其它TGFβb的降低的疾病; 家庭信号传导活动是可取的。

公开(公告)号：USD463466S1

公开(公告)日：2002-09-24

申请号：US29141468

申请日：2001-05-07

Applicant: Michael Hoemann

Designer： Michael Hoemann

公开(公告)号：US20060211864A1

公开(公告)日：2006-09-21

申请号：US11364506

申请日：2006-02-28

Applicant: Brian Aquila ,  Thomas Bannister ,  Gregory Cuny ,  James Hauske ,  Michele Heffernan ,  Michael Hoemann ,  Donald Kessler ,  Liming Shao ,  Xinhe Wu ,  Roger Xie

Inventor： Brian Aquila ,  Thomas Bannister ,  Gregory Cuny ,  James Hauske ,  Michele Heffernan ,  Michael Hoemann ,  Donald Kessler ,  Liming Shao ,  Xinhe Wu ,  Roger Xie

IPC: C07D211/06 ,  C07D211/60 ,  C07D211/26 ,  C07D211/28

CPC classification number: C07D211/22 ,  C07D211/26

Abstract: One aspect of the present invention relates to methods of synthesizing substituted piperidines. A second aspect of the present invention relates to stereoselective methods of synthesizing substituted piperidines. The methods of the present invention will find use in the synthesis of compounds useful for treatment of numerous ailments, conditions and diseases that afflict mammals, including but not limited to addiction and pain. An additional aspect of the present invention relates to the synthesis of combinatorial libraries of the substituted piperidines using the methods of the present invention. An additional aspect of the present invention relates to enantiomerically substituted pyrrolidines, piperidines, and azepines.

公开(公告)号：US20120040951A1

公开(公告)日：2012-02-16

申请号：US13142603

申请日：2009-12-30

Applicant: Claudio Chuaqui ,  Jennifer Cossrow ,  James Dowling ,  Bing Guan ,  Michael Hoemann ,  Alexey Ishchenko ,  John Howard Jones ,  Lori Kabigting ,  Gnanasambandam Kumaravel ,  Hairuo Peng ,  Noel Powell ,  Brian Raimundo ,  Hiroko Tanaka ,  Kurt van Vloten ,  Jeffrey Vessels ,  Zhili Xin

Inventor： Claudio Chuaqui ,  Jennifer Cossrow ,  James Dowling ,  Bing Guan ,  Michael Hoemann ,  Alexey Ishchenko ,  John Howard Jones ,  Lori Kabigting ,  Gnanasambandam Kumaravel ,  Hairuo Peng ,  Noel Powell ,  Brian Raimundo ,  Hiroko Tanaka ,  Kurt van Vloten ,  Jeffrey Vessels ,  Zhili Xin

IPC: A61K31/437 ,  A61K31/5377 ,  C07D417/14 ,  A61P35/00 ,  A61P9/00 ,  A61P25/28 ,  A61P37/00 ,  A61P37/06 ,  A61P29/00 ,  A61P31/12 ,  A61P19/08 ,  A61P1/16 ,  A61P7/00 ,  A61P3/10 ,  C12N9/99 ,  C07D471/04

CPC classification number: C07D261/08 ,  C07D409/12 ,  C07D413/12 ,  C07D413/14 ,  C07D417/12 ,  C07D417/14 ,  C07D471/04 ,  C07D487/04 ,  C07D513/04

Abstract: The present invention provides compounds of formula (I) useful as inhibitors of Raf protein kinase. The present invention also provides compositions thereof, and methods of treating Raf-mediated diseases.

Abstract translation: 本发明提供了可用作Raf蛋白激酶抑制剂的式（I）化合物。 本发明还提供了其组合物，以及Raf介导的疾病的治疗方法。

公开(公告)号：US20070225331A1

公开(公告)日：2007-09-27

申请号：US11803670

申请日：2007-05-14

Applicant: Michael Hoemann

Inventor： Michael Hoemann

IPC: A61K31/445 ,  C07D227/02

CPC classification number: C07D211/26 ,  C07D211/22

Abstract: One aspect of the present invention relates to heterocyclic compounds. A second aspect of the present invention relates to the use of the heterocyclic compounds as ligands for various mammalian cellular receptors, including dopamine transporters. The compounds of the present invention will find use in the treatment of numerous ailments, conditions and diseases which afflict mammals, including but not limited to addiction, anxiety, depression, sexual dysfunction, hypertension, migraine, Alzheimer's disease, obesity, emesis, psychosis, analgesia, schizophrenia, Parkinson's disease, restless leg syndrome, sleeping disorders, attention deficit hyperactivity disorder, irritable bowel syndrome, premature ejaculation, menstrual dysphoria syndrome, urinary incontinence, inflammatory pain, neuropathic pain, Lesche-Nyhane disease, Wilson's disease, and Tourette's syndrome. An additional aspect of the present invention relates to the synthesis of combinatorial libraries of the heterocyclic compounds, and the screening of those libraries for biological activity, e.g., in assays based on dopamine transporters.